A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 110 sites in 13 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one has the largest enrollment, is one of 2 that started in 2018, is one of 19 in phase 3, and was the 2nd registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2018.
This study's enrollment of 507 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 120 across the 23 interventional studies. Of the 18 that completed or were terminated, 17 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 23 have an industry lead sponsor. The 4 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 8th largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2018, is one of 62 in phase 3, and was the 74th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
2 of the studies testing elexacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The study evaluates the long-term safety and tolerability of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment Period: Participants received ELX 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hrs (q12h) in the treatment period for 192 weeks. Extension Period: Participants from certain countries participated in extension period and continued to receive ELX 200 mg qd /TEZ 100 mg qd/IVA 150 mg q12h in the extension period for 48 weeks.
Drug: ELX/TEZ/IVA · Drug: IVA
Drug pages: Elexacaftor · Tezacaftor · Ivacaftor
Fixed-dose combination (FDC) tablet for oral administration.
Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor
Tablet for oral administration.
Also known as: VX-770, ivacaftor
Treatment Period: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to Week 196
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 102/105 Efficacy Set
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
Time frame: From Baseline at Week 192
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/105 Efficacy Set
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
Time frame: From Baseline at Week 192
Absolute Change in Sweat Chloride (SwCl) for 102/105 Efficacy Set
Sweat samples were collected using an approved collection device. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
Time frame: From Baseline at Week 192
Absolute Change in Sweat Chloride (SwCl) for 103/105 Efficacy Set
Sweat samples were collected using an approved collection device. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
Time frame: From Baseline at Week 192
Number of Pulmonary Exacerbations (PEx) for 102/105 Efficacy Set
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
Time frame: From Baseline at Week 192
Number of Pulmonary Exacerbations (PEx) for 103/105 Efficacy Set
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
Time frame: From Baseline at Week 192
Time to First PEx for 102/105 Efficacy Set
Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
Time frame: From Baseline at Week 192
Time to First PEx for 103/105 Efficacy Set
Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
Time frame: From Baseline at Week 192
Absolute Change in Body Mass Index (BMI) for 102/105 Efficacy Set
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
Time frame: From Baseline at Week 192
Absolute Change in Body Mass Index (BMI) for 103/105 Efficacy Set
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
Time frame: From Baseline at Week 192
Absolute Change in BMI Z-score for 102/105 Efficacy Set
BMI was defined as weight in kg divided by height in m\^2. Z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
Time frame: From Baseline at Week 192
Absolute Change in BMI Z-score for 103/105 Efficacy Set
BMI was defined as weight in kg divided by height in m\^2. Z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
Time frame: From Baseline at Week 192
Absolute Change in Body Weight for 102/105 Efficacy Set
This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
Time frame: From Baseline at Week 192
Absolute Change in Body Weight for 103/105 Efficacy Set
This analysis set included study 103 parent study participants who received TEZ/IVA and ELX/TEZ/IVA.
Time frame: From Baseline at Week 192
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 102/105 Efficacy Set
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
Time frame: From Baseline at Week 192
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 103/105 Efficacy Set
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. This analysis set included study 103 parent study participants who received TEZ/IVA and ELX/TEZ/IVA.
Time frame: From Baseline at Week 192
The study was conducted as a single period i.e. treatment period in countries including United States (US) with commercially-available ELX/TEZ/IVA. The regional protocol for other countries without commercially-available ELX/TEZ/IVA was amended so that participants in these countries had the opportunity to participate for up to an additional 48 weeks in extension period.
| Milestone | ELX/TEZ/IVA | Additional Participants for Cumulative TC Efficacy Set |
|---|---|---|
| Started | 507 | 3 |
| Open-label safety set (ol-ss) | 506 | 0 |
| Ol-fas 102/105 | 399 | 0 |
| Ol-fas 103/105 | 107 | 0 |
| Cumulative triple combination (tc) efficacy set 102/105 | 400 | 3 |
| Cumulative tc efficacy set 103/105 | 107 | 0 |
| Completed | 354 | 0 |
| Not completed | 153 | 3 |
| Withdrew: Adverse event | 15 | 0 |
| Withdrew: Withdrawal of consent (not due to ae) | 18 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 |
| Withdrew: Commercial drug is available for participant | 48 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Other non-compliance | 2 | 0 |
| Withdrew: Physician decision | 6 | 0 |
| Withdrew: Other | 58 | 0 |
| Withdrew: Enrolled but never dosed | 1 | 0 |
| Withdrew: Not enrolled in 105 study | 0 | 3 |
| Participants | ELX/TEZ/IVA |
|---|---|
| Participants With TEAEs | 504 |
| Participants With SAEs | 175 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
| percentage points | ELX/TEZ/IVA |
|---|---|
| Placebo-ELX/TEZ/IVA | 15.3 ± 0.8 |
| ELX/TEZ/IVA-ELX/TEZ/IVA | 13.8 ± 0.8 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
| percentage points | ELX/TEZ/IVA |
|---|---|
| TEZ/IVA-ELX/TEZ/IVA | 10.9 ± 1.3 |
| ELX/TEZ/IVA-ELX/TEZ/IVA | 10.7 ± 1.3 |
Sweat samples were collected using an approved collection device. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
| millimole per liter (mmol/L) | ELX/TEZ/IVA |
|---|---|
| Placebo-ELX/TEZ/IVA | -47.0 ± 1.6 |
| ELX/TEZ/IVA-ELX/TEZ/IVA | -45.3 ± 1.6 |
Sweat samples were collected using an approved collection device. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
| mmol/L | ELX/TEZ/IVA |
|---|---|
| TEZ/IVA-ELX/TEZ/IVA | -48.2 ± 3.8 |
| ELX/TEZ/IVA-ELX/TEZ/IVA | -48.2 ± 3.5 |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
| PEx events | ELX/TEZ/IVA |
|---|---|
| Number of Pulmonary Exacerbations (PEx) for 102/105 Efficacy Set | 174 |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
| PEx events | ELX/TEZ/IVA |
|---|---|
| Number of Pulmonary Exacerbations (PEx) for 103/105 Efficacy Set | 43 |
Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
| days | ELX/TEZ/IVA |
|---|---|
| Time to First PEx for 102/105 Efficacy Set | NA (NA to NA) |
Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
| days | ELX/TEZ/IVA |
|---|---|
| Time to First PEx for 103/105 Efficacy Set | NA (NA to NA) |
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
| kilogram per meter square (kg/m^2) | ELX/TEZ/IVA |
|---|---|
| Placebo-ELX/TEZ/IVA | 1.81 ± 0.16 |
| ELX/TEZ/IVA-ELX/TEZ/IVA | 1.74 ± 0.16 |
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
| kg/m^2 | ELX/TEZ/IVA |
|---|---|
| TEZ/IVA-ELX/TEZ/IVA | 1.72 ± 0.24 |
| ELX/TEZ/IVA-ELX/TEZ/IVA | 1.85 ± 0.22 |
BMI was defined as weight in kg divided by height in m\^2. Z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
| z-score | ELX/TEZ/IVA |
|---|---|
| Placebo-ELX/TEZ/IVA | 0.24 ± 0.09 |
| ELX/TEZ/IVA-ELX/TEZ/IVA | 0.18 ± 0.09 |
BMI was defined as weight in kg divided by height in m\^2. Z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI. This analysis set included study 103 parent study participants who received TEZ/IVA-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
| z-score | ELX/TEZ/IVA |
|---|---|
| TEZ/IVA-ELX/TEZ/IVA | 0.36 ± 0.14 |
| ELX/TEZ/IVA-ELX/TEZ/IVA | 0.24 ± 0.15 |
This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
| kg | ELX/TEZ/IVA |
|---|---|
| Placebo-ELX/TEZ/IVA | 6.6 ± 0.5 |
| ELX/TEZ/IVA-ELX/TEZ/IVA | 6.0 ± 0.5 |
This analysis set included study 103 parent study participants who received TEZ/IVA and ELX/TEZ/IVA.
| kg | ELX/TEZ/IVA |
|---|---|
| TEZ/IVA-ELX/TEZ/IVA | 6.1 ± 0.8 |
| ELX/TEZ/IVA-ELX/TEZ/IVA | 6.3 ± 0.7 |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. This analysis set included study 102 parent study participants who received Placebo-ELX/TEZ/IVA and ELX/TEZ/IVA-ELX/TEZ/IVA.
| units on a scale | ELX/TEZ/IVA |
|---|---|
| Placebo-ELX/TEZ/IVA | 15.3 ± 1.5 |
| ELX/TEZ/IVA-ELX/TEZ/IVA | 18.3 ± 1.5 |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. This analysis set included study 103 parent study participants who received TEZ/IVA and ELX/TEZ/IVA.
| units on a scale | ELX/TEZ/IVA |
|---|---|
| TEZ/IVA-ELX/TEZ/IVA | 14.8 ± 2.6 |
| ELX/TEZ/IVA-ELX/TEZ/IVA | 17.6 ± 2.4 |
Collected over Adverse events (AE) are reported separately for both Periods. Treatment period covers 1st dose till 196 weeks in treatment period; extension period covers 1st dose in extension period till safety follow-up or end of study, whichever occurs first. The actual total duration for AE collection is up to 222 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Period: ELX/TEZ/IVA | 1/506 (0.2%) | 175/506 (34.6%) | 501/506 (99%) |
| Extension Period: ELX/TEZ/IVA | 0/11 (0%) | 0/11 (0%) | 7/11 (63.6%) |
| Event | Treatment Period: ELX/TEZ/IVA | Extension Period: ELX/TEZ/IVA |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 83/506 | 0/11 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 11/506 | 0/11 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 9/506 | 0/11 |
| InfluenzaInfections and infestations | 7/506 | 0/11 |
| ConstipationGastrointestinal disorders | 6/506 | 0/11 |
| PneumoniaInfections and infestations | 6/506 | 0/11 |
| Intestinal obstructionGastrointestinal disorders | 5/506 | 0/11 |
| Alanine aminotransferase increasedInvestigations | 5/506 | 0/11 |
| Aspartate aminotransferase increasedInvestigations | 5/506 | 0/11 |
| NephrolithiasisRenal and urinary disorders | 5/506 | 0/11 |
| Event | Treatment Period: ELX/TEZ/IVA | Extension Period: ELX/TEZ/IVA |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 231/506 | 0/11 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 224/506 | 3/11 |
| HeadacheNervous system disorders | 178/506 | 0/11 |
| COVID-19Infections and infestations | 168/506 | 0/11 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 166/506 | 1/11 |
| NasopharyngitisInfections and infestations | 154/506 | 0/11 |
| PyrexiaGeneral disorders | 147/506 | 0/11 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 127/506 | 0/11 |
| Upper respiratory tract infectionInfections and infestations | 120/506 | 1/11 |
| FatigueGeneral disorders | 118/506 | 0/11 |
All participants who received at least one dose of the study drug in this open label study were included in the baseline characteristics.
| Age, Continuous(years) | ELX/TEZ/IVA |
|---|---|
| Mean | 26.7 ± 10.7 |
| Sex: Female, Male(Participants) | ELX/TEZ/IVA |
|---|---|
| Female | 251 |
| Male | 255 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| Hispanic or Latino | 21 |
| Not Hispanic or Latino | 460 |
| Not collected per local regulations | 25 |
| Race/Ethnicity, Customized(Participants) | ELX/TEZ/IVA |
|---|---|
| White | 470 |
| Black or African American | 4 |
| American Indian or Alaska Native | 1 |
| Other | 3 |
| Not collected per local regulations | 25 |
| Multiple | 3 |
Showing the first 100 of 110 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Jan 2023, 51 months.
Results were first posted in May 2024, 1 year 3 months after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 51 months is above that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →